[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Pages 29127-29128]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13416]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Barry Buchbinder, 240-627-3678; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential

[[Page 29128]]

Disclosure Agreement will be required to receive copies of unpublished 
patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Recombinant HIV-1 Envelope Protein for Vaccine Use

Description of Technology

    In pursuit of an effective vaccine to end the global HIV-1/AIDS 
pandemic, researchers at the Vaccine Research Center (``VRC'') continue 
to study the structure of HIV-1. Recently, these researchers have 
determined the three-dimensional structure of the HIV-1 Envelope 
trimeric ectodomain (``Env''), comprised of three gp120 and three gp41 
subunits, in its prefusion, mature, closed conformation.
    The researchers hypothesize that immunization with the prefusion, 
closed HIV-1 Env protein will elicit a neutralizing immune response. 
The VRC researchers engineered a portion of the HIV-1 Env trimer to 
stabilize it in this closed conformation for use as an immunogen.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     Vaccine for prevention of HIV-1 infection.
     Therapeutic vaccine for treatment of HIV-1 infection.

Competitive Advantages

     Currently, no licensed HIV-1 vaccine exists.

Development Stage

     In vitro studies characterizing the immunogen and its 
interaction with HIV antibodies.
     In vivo results including immunogenicity in rabbits and 
guinea pigs, neutralizing activity of resulting serum.
    Inventors: Peter D. Kwong (NIAID), Ivelin S. Georgiev (NIAID), 
Michael Gordon Joyce (NIAID), Marie L. Pancera (NIAID), Tongqing Zhou 
(NIAID), Priyamvada Acharya (NIAID), Jason J. Gorman (NIAID), Yongping 
Yang (NIAID), Aliaksandr A. Druz (NIAID), Guillaume Stewart-Jones 
(NIAID), Rita Chen (NIAID), Gwo-Yu Chuang (NIAID), Ulrich Baxa (NIAID), 
John R. Mascola (NIAID), Rebecca M. Lynch (NIAID), Baoshan Zhang 
(NIAID), Cheng Cheng (NIAID).
    Publications: Pancera M., et al. Structure and immune recognition 
of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-
61. [PMID: 25296255].
    Intellectual Property: HHS Reference Number E-178-2014 includes 
U.S. Provisional Patent Application No. 62/046,059 filed September 4, 
2014; U.S. Provisional Patent Application No. 62/136,480 filed March 
21, 2015; PCT Application No. PCT/US2015/048729 filed September 4, 
2015; U.S. Patent Application No. 15/508,885 filed March 3, 2017; and 
EPO Patent Application No. 15766697.5 filed March 29, 2017.
    Licensing Contact: Dr. Barry Buchbinder, 240-627-3674; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize HIV-1 immunogens for treating or 
preventing HIV-1 infection. For collaboration opportunities, please 
contact Dr. Barry Buchbinder, 240-627-3674; [email protected].

    Dated: June 14, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-13416 Filed 6-21-18; 8:45 am]
 BILLING CODE 4140-01-P